PDF(Pubmed)
Abstract：
UNASSIGNED: A national additional risk minimization measures (aRMMs) program was implemented to train pharmacists for safe supply of non-prescription Viagra Connect® (VC) to erectile dysfunction (ED) patients in United Kingdom (UK). A survey aimed to evaluate the effectiveness of aRMMs.
UNASSIGNED: A cross-sectional, web-based survey enrolled ED patients who purchased at least 1 supply of VC in UK, using a structured self-administered questionnaire. Patients were assessed for the suitability of VC and received appropriate advice from pharmacists. Descriptive statistics were used.
UNASSIGNED: The final sample had 297 patients, who reported that pharmacists inquired about blood pressure and heart comorbidities (91.9%), relevant illnesses (87.9%), medications (86.5%), ED diagnosis (82.2%), and were advised to consult their doctor regarding ED (51.2%). Furthermore, 85.5% of patients were advised on how to take VC correctly, 82.2% on possible side effects for which they might have to discontinue taking VC and consult their doctor, 80.1% on being informed that ED could be caused by underlying conditions. About 65.0% reported that they had visited (19.2%) or planned to visit (45.8%) their doctor. A majority (68.7%) also indicated that they had received advice on lifestyle modifications to manage their ED-related health risks.
UNASSIGNED: This survey provided a reasonable confirmation of the effectiveness of the VC aRMMs program and assurance that ED patients, when requesting and purchasing VC in UK pharmacies, are assessed appropriately for suitability of VC and receive the appropriate advice from pharmacists.
A national additional risk minimization measures (aRMMs) program was implemented to train pharmacists for safe supply of non-prescription VC to erectile dysfunction (ED) patients in United Kingdom (UK). A cross-sectional, web-based survey enrolled ED patients who purchased at least 1 supply of VC in UK, using a structured self-administered questionnaire. Patients were assessed for the suitability of VC and received appropriate advice from pharmacists. The final sample had 297 patients, who reported that pharmacists inquired about blood pressure and heart comorbidities, relevant illnesses, medications, ED diagnosis, and were advised to consult their doctor regarding ED. Additionally, most of the patients had consulted or planned to consult their doctors, on how to take VC correctly, on possible side effects for which they might have to discontinue taking VC and consult their doctor, on being informed that ED could be caused by underlying conditions, and on lifestyle modifications. A majority also indicated that they had received advice on lifestyle modifications to manage their ED-related health risks. This survey provided a reasonable confirmation of the effectiveness of the VC aRMMs program and assurance that ED patients, when requesting and purchasing VC in UK pharmacies, are assessed appropriately for suitability of VC and receive the appropriate advice from pharmacists.
UNASSIGNED: A cross-sectional, web-based survey enrolled ED patients who purchased at least 1 supply of VC in UK, using a structured self-administered questionnaire. Patients were assessed for the suitability of VC and received appropriate advice from pharmacists. Descriptive statistics were used.
UNASSIGNED: The final sample had 297 patients, who reported that pharmacists inquired about blood pressure and heart comorbidities (91.9%), relevant illnesses (87.9%), medications (86.5%), ED diagnosis (82.2%), and were advised to consult their doctor regarding ED (51.2%). Furthermore, 85.5% of patients were advised on how to take VC correctly, 82.2% on possible side effects for which they might have to discontinue taking VC and consult their doctor, 80.1% on being informed that ED could be caused by underlying conditions. About 65.0% reported that they had visited (19.2%) or planned to visit (45.8%) their doctor. A majority (68.7%) also indicated that they had received advice on lifestyle modifications to manage their ED-related health risks.
UNASSIGNED: This survey provided a reasonable confirmation of the effectiveness of the VC aRMMs program and assurance that ED patients, when requesting and purchasing VC in UK pharmacies, are assessed appropriately for suitability of VC and receive the appropriate advice from pharmacists.
A national additional risk minimization measures (aRMMs) program was implemented to train pharmacists for safe supply of non-prescription VC to erectile dysfunction (ED) patients in United Kingdom (UK). A cross-sectional, web-based survey enrolled ED patients who purchased at least 1 supply of VC in UK, using a structured self-administered questionnaire. Patients were assessed for the suitability of VC and received appropriate advice from pharmacists. The final sample had 297 patients, who reported that pharmacists inquired about blood pressure and heart comorbidities, relevant illnesses, medications, ED diagnosis, and were advised to consult their doctor regarding ED. Additionally, most of the patients had consulted or planned to consult their doctors, on how to take VC correctly, on possible side effects for which they might have to discontinue taking VC and consult their doctor, on being informed that ED could be caused by underlying conditions, and on lifestyle modifications. A majority also indicated that they had received advice on lifestyle modifications to manage their ED-related health risks. This survey provided a reasonable confirmation of the effectiveness of the VC aRMMs program and assurance that ED patients, when requesting and purchasing VC in UK pharmacies, are assessed appropriately for suitability of VC and receive the appropriate advice from pharmacists.
摘要：
■实施了一项国家附加风险最小化措施（aRMM）计划，以培训药剂师向英国（UK）的勃起功能障碍（ED）患者安全供应非处方伟哥连接®（VC）。一项旨在评估aRMM有效性的调查。
■A横截面，基于网络的调查纳入了在英国购买至少1份VC的ED患者，使用结构化的自我管理问卷。对患者进行了VC的适用性评估，并从药剂师那里获得了适当的建议。使用描述性统计。
■最终样本有297名患者，谁报告说药剂师询问了血压和心脏合并症（91.9％），相关疾病(87.9%)，药物（86.5%），ED诊断（82.2%），并建议就ED咨询医生(51.2%)。此外，85.5%的患者被告知如何正确服用VC，82.2％的副作用，他们可能不得不停止服用VC并咨询医生，80.1%的人被告知ED可能是由潜在疾病引起的。约65.0％的人报告说他们已经拜访（19.2％）或计划拜访（45.8％）他们的医生。大多数(68.7%)还表示，他们收到了改变生活方式的建议，以管理与ED相关的健康风险。
■这项调查为VCaRMM计划的有效性提供了合理的确认，并保证ED患者，在英国药店申请和购买VC时，适当评估VC的适用性，并接受药剂师的适当建议。
实施了一项国家附加风险最小化措施（aRMM）计划，以培训药剂师向英国（UK）的勃起功能障碍（ED）患者安全供应非处方VC。横截面，基于网络的调查纳入了在英国购买至少1份VC的ED患者，使用结构化的自我管理问卷。对患者进行了VC的适用性评估，并从药剂师那里获得了适当的建议。最终样本有297名患者，他报告说药剂师询问了血压和心脏合并症，相关疾病,药物,ED诊断,并建议咨询他们的医生关于ED。此外,大多数患者已经咨询或计划咨询他们的医生，如何正确使用VC，关于可能的副作用，他们可能不得不停止服用VC并咨询医生，在被告知ED可能是由潜在条件引起的，以及生活方式的改变。大多数人还表示，他们已经收到了关于改变生活方式的建议，以管理与ED相关的健康风险。这项调查提供了对VCaRMM计划有效性的合理确认，并保证ED患者，在英国药店申请和购买VC时，适当评估VC的适用性，并接受药剂师的适当建议。
■A横截面，基于网络的调查纳入了在英国购买至少1份VC的ED患者，使用结构化的自我管理问卷。对患者进行了VC的适用性评估，并从药剂师那里获得了适当的建议。使用描述性统计。
■最终样本有297名患者，谁报告说药剂师询问了血压和心脏合并症（91.9％），相关疾病(87.9%)，药物（86.5%），ED诊断（82.2%），并建议就ED咨询医生(51.2%)。此外，85.5%的患者被告知如何正确服用VC，82.2％的副作用，他们可能不得不停止服用VC并咨询医生，80.1%的人被告知ED可能是由潜在疾病引起的。约65.0％的人报告说他们已经拜访（19.2％）或计划拜访（45.8％）他们的医生。大多数(68.7%)还表示，他们收到了改变生活方式的建议，以管理与ED相关的健康风险。
■这项调查为VCaRMM计划的有效性提供了合理的确认，并保证ED患者，在英国药店申请和购买VC时，适当评估VC的适用性，并接受药剂师的适当建议。
实施了一项国家附加风险最小化措施（aRMM）计划，以培训药剂师向英国（UK）的勃起功能障碍（ED）患者安全供应非处方VC。横截面，基于网络的调查纳入了在英国购买至少1份VC的ED患者，使用结构化的自我管理问卷。对患者进行了VC的适用性评估，并从药剂师那里获得了适当的建议。最终样本有297名患者，他报告说药剂师询问了血压和心脏合并症，相关疾病,药物,ED诊断,并建议咨询他们的医生关于ED。此外,大多数患者已经咨询或计划咨询他们的医生，如何正确使用VC，关于可能的副作用，他们可能不得不停止服用VC并咨询医生，在被告知ED可能是由潜在条件引起的，以及生活方式的改变。大多数人还表示，他们已经收到了关于改变生活方式的建议，以管理与ED相关的健康风险。这项调查提供了对VCaRMM计划有效性的合理确认，并保证ED患者，在英国药店申请和购买VC时，适当评估VC的适用性，并接受药剂师的适当建议。
